Tenax Therapeutics (NASDAQ:TENX) Stock Rating Raised to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Tenax Therapeutics from “strong sell” to “sell,” while broader analyst coverage remains “hold” with a reported consensus price target of $14.
• Tenax reported a quarterly loss of $0.31 per share, narrower than the $0.35 loss analysts expected. The company also outlined a predictive-enrichment strategy for its amended LEVEL-2 trial protocol and said it was granted an FDA Type C meeting.
• The company faces a securities class-action lawsuit alleging misleading statements about TNX-103’s clinical prospects; the allegations have not been proven. The case adds uncertainty and potential legal costs.

Tenax Therapeutics (NASDAQ:TENX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued research reports about the stock. Evercore lowered shares of Tenax Therapeutics from an "outperform" rating to an "in-line" rating and set a $5.00 price objective for the company. in a report on Tuesday, August 11th. Guggenheim cut shares of Tenax Therapeutics from a "buy" rating to a "neutral" rating in a report on Monday, August 31st. UBS Group cut shares of Tenax Therapeutics to a "neutral" rating in a research note on Monday, August 31st. Chardan Capital lowered Tenax Therapeutics from a "buy" rating to a "neutral" rating and set a $5.00 target price for the company. in a report on Tuesday, August 11th. Finally, Roth Capital set a $5.00 price objective on shares of Tenax Therapeutics in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Tenax Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $14.00.

Tenax Therapeutics Stock Up 3.7%

Shares of NASDAQ:TENX opened at $1.69 on Friday. The business has a fifty day moving average of $1.81 and a two-hundred day moving average of $9.74. The stock has a market cap of $63.24 million, a P/E ratio of -1.22 and a beta of 0.99. Tenax Therapeutics has a 52-week low of $1.31 and a 52-week high of $19.40.

Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.04. On average, equities analysts anticipate that Tenax Therapeutics will post -1.38 earnings per share for the current year.

Insider Activity

In related news, major shareholder Adar1 Capital Management, Llc acquired 331,979 shares of Tenax Therapeutics stock in a transaction dated Wednesday, October 21st. The shares were purchased at an average cost of $1.66 per share, with a total value of $551,085.14. Following the completion of the purchase, the insider owned 7,447,000 shares of the company's stock, valued at $12,362,020. This represents a 4.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Declan Doogan acquired 53,000 shares of the stock in a transaction on Wednesday, September 16th. The stock was bought at an average cost of $1.92 per share, with a total value of $101,760.00. Following the completion of the transaction, the director owned 55,274 shares in the company, valued at $106,126.08. This trade represents a 2,330.69% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 3,682,899 shares of company stock worth $6,388,279. 10.81% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Braidwell LP bought a new stake in Tenax Therapeutics during the 2nd quarter worth approximately $8,503,000. Janus Henderson Group PLC boosted its holdings in shares of Tenax Therapeutics by 989.3% in the 1st quarter. Janus Henderson Group PLC now owns 1,815,474 shares of the specialty pharmaceutical company's stock worth $29,066,000 after purchasing an additional 1,648,808 shares during the period. ADAR1 Capital Management LLC raised its stake in shares of Tenax Therapeutics by 235.2% in the first quarter. ADAR1 Capital Management LLC now owns 213,462 shares of the specialty pharmaceutical company's stock worth $3,413,000 after purchasing an additional 149,789 shares during the last quarter. Avidity Partners Management LP purchased a new stake in Tenax Therapeutics in the 1st quarter valued at about $3,453,000. Finally, Perceptive Advisors LLC raised its holdings in Tenax Therapeutics by 229.7% during the first quarter. Perceptive Advisors LLC now owns 1,447,782 shares of the specialty pharmaceutical company's stock worth $23,150,000 after purchasing an additional 1,008,640 shares in the last quarter. Institutional investors own 1.67% of the company's stock.

Key Headlines Impacting Tenax Therapeutics

Here are the key news stories impacting Tenax Therapeutics this week:

• Positive Sentiment: Tenax reported a third-quarter loss of $0.31 per share, narrower than analysts’ expected $0.35 loss. The company also said analyses of its LEVEL trial informed a predictive-enrichment strategy for the amended LEVEL-2 protocol, and that it has been granted a Type C meeting with the FDA. Tenax reports third-quarter results and corporate update
• Neutral Sentiment: The class action’s lead-plaintiff deadline is December 28, 2026. The court has not established that the allegations are true. Johnson Fistel investor alert
• Negative Sentiment: Investors’ attention is focused on a securities class action covering purchases from November 13, 2023, through August 7, 2026. The complaint alleges Tenax and certain executives made misleading statements about TNX-103’s clinical prospects; one notice says the company raised $134 million before its Phase 3 LEVEL trial missed its primary endpoint. The litigation creates uncertainty and could add legal costs, although the claims remain allegations. TENX shareholder alert and lawsuit allegations

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company's research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax's lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.